Rheumatology

In the final part of our 3-part series, our panel of experts discuss what their fields and its leaders could do to make sure this lack of diversity in trials does not continue. These responses are highlighted in the following video and transcribed below.

In part 2 of our 3-part series on the impact of clinical trials lacking diversity, we are spotlighting responses to our second question, which addresses how the previously established lack of diversity in clinical trials has had a direct effect on the development and application of new therapies or devices in real-world settings.

In part 1 of our 3-part series on the impact of clinical trials lacking diversity, we are spotlighting responses to our first question, which sought to encapsulate the perspectives of our group of experts on how a historic lack of diversity in clinical trials has manifested itself in today’s care of patients from diverse backgrounds.

This article serves as a landing page for our 3-part series spotlighting how a lack of diversity in clinical trials has had a deleterious downstream effect on real-world care for people of color in the US, with perspective from experts across more than half a dozen specialties.

In an analysis of the DISCOVER-2 trial, guselkumab treatment reduced impairment in work productivity and improved general health status in PsA over 2 years.

Headache prevalence was significantly higher in the PsA and axSpA cohorts compared with healthy controls.

The presence of sinusitis is linked to a 40% heightened risk of a diagnosis of rheumatic disease, particularly in the 5 to 10 years before disease onset.

Most patients (82.6%) had minimal psoriasis skin involvement with a body surface area of < 3. However, 15.1% and 2.4% had a body surface area involvement of 3 – 10% and > 10, respectively.

Patients with gout and negative DECTs for monosodium urate crystal deposition exhibited milder disease and a lower comorbidity burden.

Interactions with alcohol consumption were identified at ADH1B and MLXIPL for association with serum urate level and at ADH1B for association with hyperuricemia and gout

Urate-lowering therapy and dosing regimen impact the risk of gout flares, with greater fixed dosing linked to a greater risk of flares and prophylaxis associated with reductions in flare risk.

A groundbreaking phase 1 study using CAR-T cells to treat severe lupus highlights a collaborative effort between the Cellular Therapy Program and rheumatology programs to pioneer innovative patient care.

Anisha Dua, MD, MPH, delves into recent research advancements, diagnostic hurdles, and emerging therapeutic options in vasculitis.

The study performed the first genome-wide cross-trait analysis to investigate the shared genetic basis underlying hypothyroidism and rheumatoid arthritis.

Anisha Dua, MD, MPH, sheds light on the intricate challenges posed by vasculitis and its mimics.

A Mendelian randomization analysis provided new insights into the relationship between inflammatory cytokines and ankylosing spondylitis, rheumatoid arthritis, and psoriatic arthritis.

A Finnish study finds elevated cardiovascular risk in rheumatic diseases peaks within a year of diagnosis, emphasizing the need for early management strategies.

Patients with ACPA-positive RA and obesity had greater DAS44 scores compared to normal-weight patients, although this difference was not present in ACPA-negative RA.

Patients with both rheumatoid arthritis and depression have an increased risk of mortality by more than 2 times than patients with RA but no depression, according to a new study.

Results call attention to the potential for early intervention and risk stratification for developing RA based on remnant cholesterol.

Patients with fibromyalgia have poorer accuracy for divided attention, mediated by sleep disturbance, according to a new study.

Promising results of the phase 2 and 3 trials offer hope for patients with chronic and debilitating autoantibody-driven diseases.

The Xist ribonucleoprotein (RNP) complex, linked to the XX sex chromosome complement, influences the susceptibility to autoimmunity.

The percentage of lymphocyte apoptosis in peripheral blood was significantly higher in patients with jSLE when compared with healthy controls.

Of the 135 laser flare photometry readings to identify uveitis among patients with juvenile idiopathic arthritis, only 3% were characterized as a false positive.

Patients with inflammatory arthritis demonstrated significantly increased odds of depression and anxiety health care encounters and use of anxiolytics and antidepressants.

Angus Worthing, MD, discusses the recent developments in rheumatology and his predictions for the future of treatment moving into 2024 and beyond.

Wesley Mizutani, MD, discusses California's SB 496 legislation, which addresses the crucial role of biomarkers in guiding optimal drug selection to improve overall healthcare outcomes.

In a new study, 31.9% of individuals with osteoporosis had depressive symptoms and 10% had probable depression.

A retrospective cohort analysis suggests the monoclonal antibody may help patients with SLE reduce their reliance on oral corticosteroids over 1 year after initiating treatment.